Giant Biogene Holding Co., Ltd. (HKG:2367)

Giant Biogene Holding Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,944	4,030	2,504	1,331	7,103	367.81
Short-Term Investments	-	19.5	11.03	21.31	4.88	2.41
Trading Asset Securities	1,917	1,829	1,275	865.97	155.61	1,588
Cash & Short-Term Investments	8,861	5,878	3,790	2,218	7,263	1,959
Cash Growth	46.13%	55.11%	70.85%	-69.46%	270.86%	137.40%
Accounts Receivable	466.47	141.28	102.03	69.42	65.64	54.52
Other Receivables	-	7.34	14.55	4.6	6.7	201.31
Receivables	466.47	148.62	116.57	74.02	72.34	255.83
Inventory	441.14	310.81	200.44	183.9	89.39	64.66
Other Current Assets	118.86	64.17	28.26	61.58	16.11	5.06
Total Current Assets	9,888	6,402	4,135	2,538	7,441	2,284
Property, Plant & Equipment	1,214	1,093	711.62	551.65	333.53	280.71
Long-Term Investments	105.85	451.84	-	-	-	-
Other Intangible Assets	5.48	5.82	7.36	6.75	7.6	8.78
Long-Term Deferred Tax Assets	1.23	0.91	1.11	1.19	1.35	1.23
Other Long-Term Assets	71.62	84.65	117.91	40.9	94.41	76.28
Total Assets	11,286	8,038	4,973	3,138	7,878	2,651
Accounts Payable	299.99	286.71	133.11	54.65	23.61	31.95
Accrued Expenses	-	61.36	40.72	28.5	28.93	40.51
Current Portion of Leases	5.17	4.7	1.56	0.88	-	-
Current Income Taxes Payable	105.84	117.02	116.72	75.02	71.36	144.23
Current Unearned Revenue	58.7	18.68	37.25	13.95	17.78	3.85
Other Current Liabilities	1,560	347.53	201.25	107.9	6,701	1,953
Total Current Liabilities	2,030	836	530.61	280.91	6,843	2,174
Long-Term Leases	1.78	2.01	1.17	1.71	-	-
Long-Term Unearned Revenue	17.41	18.93	19.58	18.18	17.58	17.97
Long-Term Deferred Tax Liabilities	48.18	61.2	50.68	0.4	0.77	1.24
Total Liabilities	2,097	918.14	602.03	301.19	6,861	2,193
Common Stock	0.07	0.07	0.06	0.06	0.06	-
Additional Paid-In Capital	-	2,736	1,695	1,597	7,160	-
Retained Earnings	-	4,229	2,619	1,167	164.8	-
Treasury Stock	-	-0	-0	-0	-0	-
Comprehensive Income & Other	9,177	143.53	48.81	69.72	-6,308	458
Total Common Equity	9,177	7,108	4,362	2,833	1,017	458
Minority Interest	11.97	11.61	8.91	3.56	-	-
Shareholders' Equity	9,189	7,120	4,371	2,837	1,017	458
Total Liabilities & Equity	11,286	8,038	4,973	3,138	7,878	2,651
Total Debt	6.95	6.71	2.73	2.59	-	-
Net Cash (Debt)	8,854	5,872	3,787	2,216	7,263	1,959
Net Cash Growth	46.05%	55.04%	70.92%	-69.50%	270.86%	137.40%
Net Cash Per Share	8.68	5.86	3.85	2.17	7.26	1.96
Filing Date Shares Outstanding	1,035	1,016	976	976	900	1,000
Total Common Shares Outstanding	1,035	1,016	976	976	900	1,000
Working Capital	7,858	5,566	3,604	2,257	598.28	110.21
Book Value Per Share	8.87	7.00	4.47	2.90	1.13	0.46
Tangible Book Value	9,171	7,102	4,355	2,827	1,009	449.22
Tangible Book Value Per Share	8.86	6.99	4.46	2.90	1.12	0.45
Buildings	-	580.02	285.49	225.79	184.61	171.54
Machinery	-	214.6	131.75	104.62	69.28	59.51
Construction In Progress	-	387.88	356.25	244.44	81.58	50.89
Leasehold Improvements	-	21.69	9.54	5.56	1.86	1.86

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.